Macular telangiectasia Pipeline

DelveInsight reports that more than 4 key companies are actively engaged in developing over 4 therapies for the treatment of Macular Telangiectasia.

Macular telangiectasia Overview:

Macular Telangiectasia (MacTel) is a disorder of the macula that causes gradual loss of central vision, primarily due to abnormalities in the small blood vessels surrounding the fovea.

There are two main types:

• Type 1 MacTel: Characterized by dilated blood vessels and small aneurysms that lead to swelling and damage of macular cells. This form usually affects only one eye.

• Type 2 MacTel: The more prevalent form, marked by dilation and leakage of the foveal capillaries. This leakage causes fluid accumulation and swelling, disrupting light reflection and progressively reducing vision. Over time, abnormal new blood vessels may develop, rupture, and leak, forming scar tissue that further impairs central vision. Type 2 typically involves both eyes and is most commonly seen in middle-aged adults.

Download our report @ https://www.delveinsight.com/report-store/macular-telangiectasia-mactel-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Macular telangiectasia Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Macular telangiectasia Therapeutics Market.

Key Takeaways from the Macular telangiectasia Pipeline Report:

• DelveInsight’s Macular Telangiectasia pipeline report highlights a growing field, with over 4 active companies developing more than 4 potential therapies for treatment.

• In March 2025, the U.S. FDA approved Encelto, a gene therapy implant by Neurotech Pharmaceuticals, as the first-ever approved treatment for MacTel—marking a landmark achievement in ophthalmology.

• Notable players in this space include OXURION, Neurotech Pharmaceuticals, and others, all advancing innovative drug candidates to enhance the treatment landscape.

• Promising therapies in the pipeline include NT-501, THR 317, and additional candidates in various stages of development.

Macular telangiectasia Pipeline Analysis

The Macular telangiectasia pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Macular telangiectasia Market.

• Categorizes Macular telangiectasia therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Macular telangiectasia drugs under development based on:

  • Stage of development

  • Macular telangiectasia Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Macular telangiectasia Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Macular telangiectasia Licensing agreements

  • Funding and investment activities supporting future Macular telangiectasia market advancement.

Request for a sample report @ https://www.delveinsight.com/report-store/macular-telangiectasia-mactel-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Macular telangiectasia Emerging Drugs

• NT-501: Neurotech Pharmaceuticals

NT-501 (Renexus) is an encapsulated cell therapy developed for the treatment of Macular Telangiectasia (MacTel). It is currently being evaluated in a Phase 3 randomized, multi-center trial to determine the safety and effectiveness of Renexus implants in patients with Type 2 MacTel.

This therapy uses an innovative cell-based drug delivery system, in which human-derived cells are enclosed within a semipermeable hollow fiber membrane device that continuously releases ciliary neurotrophic factor (CNTF).

NT-501 has also received key regulatory designations: orphan drug status from the FDA in July 2012 for Type 2 MacTel, and Fast Track designation in February 2019 for the same indication.

• THR 317: OXURION

THR-317, a Placenta Growth Factor (PlGF) inhibitor, is currently in a Phase II clinical trial for the treatment of Idiopathic Macular Telangiectasia (MacTel) Type 1.

Macular telangiectasia Companies

More than 4 major companies are developing therapies for Macular Telangiectasia (MacTel), with Neurotech Pharmaceuticals leading the field as its drug candidates have reached the most advanced stage of development, Phase III.

DelveInsight’s report covers around 4+ products under different phases of Macular telangiectasia clinical trials like

• Macular telangiectasia Late stage Therapies (Phase III)

• Macular telangiectasia Mid-stage Therapies (Phase II)

• Macular telangiectasia Early-stage Therapies (Phase I)

• Macular telangiectasia Pre-clinical and Macular telangiectasia Discovery stage Therapies

• Macular telangiectasia Discontinued & Inactive Therapies

Macular telangiectasia pipeline report provides the Macular telangiectasia therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Macular telangiectasia Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Macular telangiectasia Therapies and Key Macular telangiectasia Companies: Macular telangiectasia Clinical Trials and recent advancements

Macular telangiectasia Pipeline Therapeutic Assessment

• Macular telangiectasia Assessment by Product Type

• Macular telangiectasia By Stage

• Macular telangiectasia Assessment by Route of Administration

• Macular telangiectasia Assessment by Molecule Type

Download Macular telangiectasia Sample report to know in detail about the Macular telangiectasia treatment market @ Macular telangiectasia Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Macular telangiectasia Current Treatment Patterns

4. Macular telangiectasia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Macular telangiectasia Late-Stage Products (Phase-III)

7. Macular telangiectasia Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Macular telangiectasia Discontinued Products

13. Macular telangiectasia Product Profiles

14. Macular telangiectasia Key Companies

15. Macular telangiectasia Key Products

16. Dormant and Discontinued Products

17. Macular telangiectasia Unmet Needs

18. Macular telangiectasia Future Perspectives

19. Macular telangiectasia Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Macular telangiectasia Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/